Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 16/20 | 0.54 |
| ▸ | SELL | P14151 | 6/20 | 0.41 |
| ▸ | SELP | P16109 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777231 | 0.90 | SELE (0.50) | SELESELLSELP | |
| SCHEMBL17881699 | 0.87 | SELE (0.45) | SELESELLSELP | |
| SCHEMBL17881669 | 0.86 | SELE (0.48) | SELESELLSELP | |
| SCHEMBL16661872 | 0.83 | SELE (0.42) | SELESELLSELP | |
| SCHEMBL15070071 | 0.82 | SELE (0.58) | SELESELP | |
| SCHEMBL19491946 | 0.81 | SELE (0.50) | SELESELP | |
| SCHEMBL16661824 | 0.79 | SELE (0.49) | SELESELLSELP | |
| SCHEMBL16659815 | 0.79 | SELE (0.70) | SELE | |
| SCHEMBL17881698 | 0.79 | SELE (0.70) | SELE | |
| SCHEMBL15070099 | 0.79 | SELE (0.70) | SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160243145-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | GLYCOMIMETICS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160184339-A1 | Compounds, Compositions and Methods Using E-Selectin Antagonists for Mobilization of Hematopoietic Cells | GLYCOMIMETICS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9109002-B2 | E-selectin antagonist compounds, compositions, and methods of use | GLYCOMIMETICS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150110808-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150110808-A1 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SELE, SELPLG, SELP | SELE 1/4885SELL 4/4885SELP 3/4885 |
| US-20160243145-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | SELE, SELP, SELPLG | SELE 1/4885SELL 4/4885SELP 2/4885 |
| US-20160184339-A1 | Compounds, Compositions and Methods Using E-Selectin Antagonists for Mobilization of Hematopoietic Cells | SELE, SELP, SELPLG | SELE 1/4885SELL 4/4885SELP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.